Table 3

Clinicopathological and genetic characteristics of Omani CRC cases.


Omani






All
non-MSI-H
MSI-H
Odds Ratio
P

Number of patients
61
53 (87)a
8 (13)a


Mean Age
52.7+13.6
-
53.1+12.8
-
51.5+19.2
-

0.76
Gender




0.37
     Female
24 (39)
22 (42)
2 (25)
1

     Male
37 (61)
31(58)
6 (75)
2.12(0.39–11.55)

Site
61



0.75
     Distal
51 (84)
44(83)
7(87)
1

     Proximal
10 (16)
9(17)
1(13)
1.43(0.16–13.11)

Mucin Production
61



0.44
     None
47 (77)
42(78)
5 (63)
1

     < 50%
14(23)
11 (20)
3(37)
2.3(0.47–11.10)

     > 50%
0
0
0
NA

Differentiation
60



0.44
     Well
7 (12)
7 (14)
0
NA

     Moderate
49(82)
43 (81)
6(86)
1

     Poor
4 (6)
3 (6)
1 (14)
2.39(0.21–26.84)

Stage
61



0.28
     Stage 1
1 (2)
1 (2)
0
NA

     Stage 2
20 (33)
15 (28)
5 (62)
1

     Stage 3
31 (50)
29 (55)
2 (25)
0.21(0.02–1.50)

     Stage 4
9 (15)
8 (15)
1 (13)
0.38(0.01–4.41)

BRAF
59



0.62
     Wild type
48 (81)
42 (82)
6 (75)
1

     V600E
11 (19)
9 (18)
2 (25)
1.56(0.27–9.0)

hMLH1 methylation (MSP)
49



0.47
     Unmethylation
8 (16)
6(14.6)
2 (25)
1

     Methylation
41 (84)
35 (85.4)
6 (75)
0.51(0.08–3.17)

p16 methylation (MSP)
44



0.09
     Unmethylation
27(62)
20 (56)
7 (88)
1

     Methylation
17 (38)
16 (44)
1 (12)
0.18(0.02–1.61)

hMLH1 expression by IHC
61



0.68
     Normal
42 (69)
37(70)
5 (62)
1

     Negative
19 (32)
16 (30)
3(38)
1.39(0.29–6.67)

hMSH2 expression by IHC
61



0.63
     Normal
56 (92)
49 (92)
7(87)
1

     Negative
5 (8)
4 (8)
1(13)
1.75(0.17–16.67)


Parentheses indicate percentages: All values are based on column except a based on row. MSP = methylation-specific PCR; IHC = immunohistochemistry

Brim et al. Molecular Cancer 2008 7:68   doi:10.1186/1476-4598-7-68